Table 1.
Second Derivative | First Derivative | Fibrin Formation | |||||
---|---|---|---|---|---|---|---|
APTT | Peak Time | Peak Height | Peak Time | Peak Width | Peak Height | Peak Time | Peak Height |
HVs | 36.8 (35.6–38.9) |
731 (600–804) |
34.7 (33.7–36.6) |
36.0 (31.1–42.0) |
231 (201–273) |
36.8 (35.6–38.9) |
196 (171–214) |
CLD | 35.8 (33.1–38.4) |
888 *** (752–1033) |
33.8 (31.4–36.5) |
35.0 (31.5–42.1) |
292 *** (246–339) |
35.8 (33.1–38.4) |
220 *** (198–250) |
Cancer | 36.8 (34.1–38.2) |
955 *** (824–1168) |
34.3 (31.8–36.1) |
41.1 *** (34.9–46.5) |
315 *** (268–394) |
36.8 (34.1–38.2) |
253 *** (217–308) |
ACI | 35.8 (33.3–38.1) |
997 *** (853–1191) |
33.7 (31.4–36.1) |
37.7 (33.0–42.8) |
327 *** (276–404) |
35.8 (33.3–38.1) |
239 *** (211–282) |
AMI | 39.2 ** (35.4–44.8) |
1069 *** (865–1374) |
37.6 ** (33.6–42.0) |
42.5 *** (37.4–50.5) |
400 *** (324–495) |
39.2 ** (35.4–44.8) |
324 *** (273–395) |
sTF/FIXa | Peak time | Peak height | Peak time | Peak width | Peak height | Peak time | Peak height |
HVs | 71.3 (65.1–79.2) |
31.9 (28.7–40.0) |
91.3 (85.8–98.0) |
145 (134–158) |
65.0 (55.4–71.9) |
92.2 (86.9–97.8) |
315 (255–373) |
CLD | 68.2 * (61.5–64.7) |
44.5 *** (36.6–56.9) |
84.5 *** (78.8–90.4) |
138 *** (126–145) |
83.6 *** (71.3–101) |
85.7 *** (79.7–91.3) |
330 (277–380) |
Cancer | 70.5 (62.7–79.3) |
43.1 *** (31.3–62.1) |
90.1 (79.8–100) |
152 (131–170) |
88.3 *** (73.2–114) |
92.4 (81.7–102) |
344 * (284–432) |
ACI | 63.8 ** (54.3–74.0) |
47.0 *** (36.2–60.1) |
85.3 ** (77.0–94.4) |
142 (132–154) |
91.1 *** (75.6–118) |
85.8 *** (78.2–94.6) |
347 ** (302–413) |
AMI | 68.1 (56.6–77.4) | 46.8 *** (33.0–60.2) |
93.0 (84.0–107) |
162 *** (142–183) |
112 *** (81.1–138) |
94.6 (84.5–108) |
473 *** (393–550) |
CWA, clot waveform analysis; APTT, activated partial thromboplastin time; sTF/FIXa, small amount of tissue factor activation assay; HVs, healthy volunteers; CLD, chronic liver disease, ACI, acute cerebral infarction; AMI, acute myocardial infarction; *, p < 0.05; **, p < 0.01; ***, p < 0.001 in comparison to HVs.